Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

F. Davies, R. Rifkin, C. Costello, G. Morgan, S. Usmani, R. Abonour, A. Palumbo, D. Romanus, R. Hajek, E. Terpos, D. Cherepanov, DM. Stull, H. Huang, X. Leleu, J. Berdeja, HC. Lee, K. Weisel, M. Thompson, M. Boccadoro, J. Zonder, G. Cook, N....

. 2021 ; 100 (9) : 2325-2337. [pub] 20210510

Jazyk angličtina Země Německo

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024985

Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights the need for real-world (RW) evidence. We conducted an RW comparative effectiveness analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and daratumumab (D) combined with either lenalidomide or pomalidomide plus dexamethasone (Rd or Pd) in RRMM. A retrospective cohort of patients initiating triplet regimens in line of therapy (LOT) ≥ 2 on/after 1/1/2014 was followed between 1/2007 and 3/2018 in Optum's deidentified US electronic health records database. Time to next treatment (TTNT) was estimated using Kaplan-Meier methods; regimens were compared using covariate-adjusted Cox proportional hazard models. Seven hundred forty-one patients (820 patient LOTs) with an Rd backbone (VRd, n = 349; KRd, n = 218; DRd, n = 99; IRd, n = 154) and 348 patients (392 patient LOTs) with a Pd backbone (VPd, n = 52; KPd, n = 146; DPd, n = 149; IPd, n = 45) in LOTs ≥2 were identified. More patients ≥75 years received IRd (39.6%), IPd (37.8%), and VRd (36.7%) than other triplets. More patients receiving VRd/VPd were in LOT2 vs other triplets. Unadjusted median TTNT in LOT ≥ 2: VRd, 13.9; KRd, 8.7; IRd, 11.4; DRd, not estimable (NE); and VPd, 12.0; KPd, 6.7; IPd, 9.5 months; DPd, NE. In covariate-adjusted analysis, only KRd vs DRd was associated with a significantly higher risk of next LOT initiation/death (HR 1.72; P = 0.0142); no Pd triplet was significantly different vs DPd in LOT ≥ 2. Our data highlight important efficacy/effectiveness gaps between results observed in phase 3 clinical trials and those realized in the RW.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024985
003      
CZ-PrNML
005      
20211026134230.0
007      
ta
008      
211013s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-021-04534-8 $2 doi
035    __
$a (PubMed)33970288
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Davies, Faith $u NYU Langone Health, New York, NY, USA. faith.davies@nyulangone.org
245    10
$a Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US / $c F. Davies, R. Rifkin, C. Costello, G. Morgan, S. Usmani, R. Abonour, A. Palumbo, D. Romanus, R. Hajek, E. Terpos, D. Cherepanov, DM. Stull, H. Huang, X. Leleu, J. Berdeja, HC. Lee, K. Weisel, M. Thompson, M. Boccadoro, J. Zonder, G. Cook, N. Puig, J. Vela-Ojeda, E. Farrelly, A. Raju, M. Blazer, A. Chari
520    9_
$a Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights the need for real-world (RW) evidence. We conducted an RW comparative effectiveness analysis of bortezomib (V), carfilzomib (K), ixazomib (I), and daratumumab (D) combined with either lenalidomide or pomalidomide plus dexamethasone (Rd or Pd) in RRMM. A retrospective cohort of patients initiating triplet regimens in line of therapy (LOT) ≥ 2 on/after 1/1/2014 was followed between 1/2007 and 3/2018 in Optum's deidentified US electronic health records database. Time to next treatment (TTNT) was estimated using Kaplan-Meier methods; regimens were compared using covariate-adjusted Cox proportional hazard models. Seven hundred forty-one patients (820 patient LOTs) with an Rd backbone (VRd, n = 349; KRd, n = 218; DRd, n = 99; IRd, n = 154) and 348 patients (392 patient LOTs) with a Pd backbone (VPd, n = 52; KPd, n = 146; DPd, n = 149; IPd, n = 45) in LOTs ≥2 were identified. More patients ≥75 years received IRd (39.6%), IPd (37.8%), and VRd (36.7%) than other triplets. More patients receiving VRd/VPd were in LOT2 vs other triplets. Unadjusted median TTNT in LOT ≥ 2: VRd, 13.9; KRd, 8.7; IRd, 11.4; DRd, not estimable (NE); and VPd, 12.0; KPd, 6.7; IPd, 9.5 months; DPd, NE. In covariate-adjusted analysis, only KRd vs DRd was associated with a significantly higher risk of next LOT initiation/death (HR 1.72; P = 0.0142); no Pd triplet was significantly different vs DPd in LOT ≥ 2. Our data highlight important efficacy/effectiveness gaps between results observed in phase 3 clinical trials and those realized in the RW.
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a sloučeniny boru $x terapeutické užití $7 D001896
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glycin $x analogy a deriváty $x terapeutické užití $7 D005998
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a oligopeptidy $x terapeutické užití $7 D009842
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rifkin, Robert $u Rocky Mountain Cancer Centers, Denver, CO, USA
700    1_
$a Costello, Caitlin $u Moores Cancer Center, University of California, San Diego, CA, USA
700    1_
$a Morgan, Gareth $u NYU Langone Health, New York, NY, USA
700    1_
$a Usmani, Saad $u Carolinas Healthcare System, Charlotte, NC, USA
700    1_
$a Abonour, Rafat $u Indiana University, Indianapolis, IN, USA
700    1_
$a Palumbo, Antonio $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
700    1_
$a Romanus, Dorothy $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
700    1_
$a Hajek, Roman $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Terpos, Evangelos $u University of Athens School of Medicine, Athens, Greece
700    1_
$a Cherepanov, Dasha $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
700    1_
$a Stull, Dawn Marie $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
700    1_
$a Huang, Hui $u Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA
700    1_
$a Leleu, Xavier $u CHU la Miletrie, Poiters, France
700    1_
$a Berdeja, Jesus $u Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN, USA
700    1_
$a Lee, Hans C $u University of Texas, MD Anderson Cancer Center, Houston, TX, USA
700    1_
$a Weisel, Katja $u Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Thompson, Michael $u Aurora Cancer Center, Advocate Aurora Health, Milwaukee, WI, USA
700    1_
$a Boccadoro, Mario $u Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy
700    1_
$a Zonder, Jeffrey $u Karmanos Cancer Institute, Detroit, MI, USA
700    1_
$a Cook, Gordon $u Leeds Teaching Hospitals NHS Trust, Leeds, UK
700    1_
$a Puig, Noemi $u Salamanca University Hospital, Salamanca, Spain
700    1_
$a Vela-Ojeda, Jorge $u Hospital de Especialidades Centro Medico Nacional la Raza, Mexico City, Mexico
700    1_
$a Farrelly, Eileen $u Xcenda, Palm Harbor, FL, USA
700    1_
$a Raju, Aditya $u Xcenda, Palm Harbor, FL, USA
700    1_
$a Blazer, Marlo $u Xcenda, Palm Harbor, FL, USA
700    1_
$a Chari, Ajai $u Icahn School of Medicine at Mount Sinai, New York, NY, USA
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 100, č. 9 (2021), s. 2325-2337
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33970288 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134236 $b ABA008
999    __
$a ok $b bmc $g 1714154 $s 1145492
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 100 $c 9 $d 2325-2337 $e 20210510 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace